COGT
$33.38-1.23 (-3.55%)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Recent News
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.